169 related articles for article (PubMed ID: 11559318)
1. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease.
Schulte T; Mattern R; Berger K; Szymanski S; Klotz P; Kraus PH; Przuntek H; Schöls L
Arch Neurol; 2001 Sep; 58(9):1451-7. PubMed ID: 11559318
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of sulphametoxazole and trimethoprim in patients with Machado-Joseph disease.
Correia M; Coutinho P; Silva MC; Guimarães J; Amado J; Matos E
Rev Neurol; 1995; 23(121):632-4. PubMed ID: 8597984
[TBL] [Abstract][Full Text] [Related]
3. Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin.
Sakai T; Matsuishi T; Yamada S; Komori H; Iwashita H
J Neural Transm Gen Sect; 1995; 102(2):159-72. PubMed ID: 8748680
[TBL] [Abstract][Full Text] [Related]
4. Contrast sensitivity improvement with sulfamethoxazole and trimethoprim in a patient with Machado-Joseph disease without spasticity.
Azulay JP; Blin O; Mestre D; Sangla I; Serratrice G
J Neurol Sci; 1994 May; 123(1-2):95-9. PubMed ID: 8064328
[TBL] [Abstract][Full Text] [Related]
5. Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial.
Saute JA; Rieder CR; Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; Souza DO; Saraiva-Pereira ML; Portela LV; Camey S; Torman VB; Jardim LB
J Neurol Sci; 2015 Nov; 358(1-2):72-6. PubMed ID: 26297649
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of valproic acid treatment in SCA3/MJD patients.
Lei LF; Yang GP; Wang JL; Chuang DM; Song WH; Tang BS; Jiang H
Parkinsonism Relat Disord; 2016 May; 26():55-61. PubMed ID: 26997655
[TBL] [Abstract][Full Text] [Related]
7. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease.
Saute JA; de Castilhos RM; Monte TL; Schumacher-Schuh AF; Donis KC; D'Ávila R; Souza GN; Russo AD; Furtado GV; Gheno TC; de Souza DO; Portela LV; Saraiva-Pereira ML; Camey SA; Torman VB; de Mello Rieder CR; Jardim LB
Mov Disord; 2014 Apr; 29(4):568-73. PubMed ID: 24399647
[TBL] [Abstract][Full Text] [Related]
8. Age related axonal neuropathy in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD).
Klockgether T; Schöls L; Abele M; Bürk K; Topka H; Andres F; Amoiridis G; Lüdtke R; Riess O; Laccone F; Dichgans J
J Neurol Neurosurg Psychiatry; 1999 Feb; 66(2):222-4. PubMed ID: 10071104
[TBL] [Abstract][Full Text] [Related]
9. [A possibility of therapeutic trial with tetrahydrobiopterin, which was suggested by the administration of sulfamethoxazole-trimethoprim].
Sakai T
Rinsho Shinkeigaku; 1996 Dec; 36(12):1324-5. PubMed ID: 9128394
[TBL] [Abstract][Full Text] [Related]
10. Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM; Jardim LB
Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
[TBL] [Abstract][Full Text] [Related]
11. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds.
Tang B; Liu C; Shen L; Dai H; Pan Q; Jing L; Ouyang S; Xia J
Arch Neurol; 2000 Apr; 57(4):540-4. PubMed ID: 10768629
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance spectroscopy of the cerebellum in patients with spinocerebellar ataxia type 3/Machado-Joseph disease.
Lei L; Liao Y; Liao W; Zhou J; Yuan Y; Wang J; Jiang H; Shen L; Tang B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 36(6):511-9. PubMed ID: 21743142
[TBL] [Abstract][Full Text] [Related]
13. Spinocerebellar ataxia type 3/Machado-Joseph disease starting before adolescence.
Donis KC; Saute JA; Krum-Santos AC; Furtado GV; Mattos EP; Saraiva-Pereira ML; Torman VL; Jardim LB
Neurogenetics; 2016 Apr; 17(2):107-13. PubMed ID: 26780339
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of NSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease.
Zhou J; Lei L; Shi Y; Wang J; Jiang H; Shen L; Tang B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 36(6):504-10. PubMed ID: 21743141
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.
Talan DA; Stamm WE; Hooton TM; Moran GJ; Burke T; Iravani A; Reuning-Scherer J; Church DA
JAMA; 2000 Mar 22-29; 283(12):1583-90. PubMed ID: 10735395
[TBL] [Abstract][Full Text] [Related]
16. Case report: Short-term efficacy and changes in
Cui Z; Lan Y; Chang Y; Liu X; Wang J; Lou X; Wang R
Front Neurol; 2023; 14():1246430. PubMed ID: 37830087
[TBL] [Abstract][Full Text] [Related]
17. Sleep apnea in Machado-Joseph disease: a clinical and polysomnographic evaluation.
Folha Santos FA; de Carvalho LBC; Prado LFD; do Prado GF; Barsottini OG; Pedroso JL
Sleep Med; 2018 Aug; 48():23-26. PubMed ID: 29852360
[TBL] [Abstract][Full Text] [Related]
18. High Serum GFAP Levels in SCA3/MJD May Not Correlate with Disease Progression.
Shi Y; Wang C; Huang F; Chen Z; Sun Z; Wang J; Tang B; Ashizawa T; Klockgether T; Jiang H
Cerebellum; 2015 Dec; 14(6):677-81. PubMed ID: 25869927
[TBL] [Abstract][Full Text] [Related]
19. Cognitive deficits in Machado-Joseph disease correlate with hypoperfusion of visual system areas.
Braga-Neto P; Dutra LA; Pedroso JL; Felício AC; Alessi H; Santos-Galduroz RF; Bertolucci PH; Castiglioni ML; Bressan RA; de Garrido GE; Barsottini OG; Jackowski A
Cerebellum; 2012 Dec; 11(4):1037-44. PubMed ID: 22307858
[TBL] [Abstract][Full Text] [Related]
20. The correlation between magnetic resonance imaging features of the brainstem and cerebellum and clinical features of spinocerebellar ataxia 3/Machado-Joseph disease.
Liang X; Jiang H; Chen C; Zhou G; Wang J; Zhang S; Lei L; Wang X; Tang B
Neurol India; 2009; 57(5):578-83. PubMed ID: 19934555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
